Horowitz L F, Rodriguez A D, Dereli-Korkut Z, Lin R, Castro K, Mikheev A M, Monnat R J, Folch A, Rostomily R C
1Department of Bioengineering, University of Washington, Seattle, WA 98195 USA.
2Department of Neurosurgery, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98195 USA.
NPJ Precis Oncol. 2020 May 19;4:12. doi: 10.1038/s41698-020-0117-y. eCollection 2020.
Current methods to assess the drug response of individual human cancers are often inaccurate, costly, or slow. Functional approaches that rapidly and directly assess the response of patient cancer tissue to drugs or small molecules offer a promising way to improve drug testing, and have the potential to identify the best therapy for individual patients. We developed a digitally manufactured microfluidic platform for multiplexed drug testing of intact cancer slice cultures, and demonstrate the use of this platform to evaluate drug responses in slice cultures from human glioma xenografts and patient tumor biopsies. This approach retains much of the tissue microenvironment and can provide results rapidly enough, within days of surgery, to guide the choice of effective initial therapies. Our results establish a useful preclinical platform for cancer drug testing and development with the potential to improve cancer personalized medicine.
当前评估个体人类癌症药物反应的方法往往不准确、成本高或速度慢。能够快速、直接评估患者癌组织对药物或小分子反应的功能方法为改进药物测试提供了一种有前景的途径，并且有潜力为个体患者确定最佳治疗方案。我们开发了一种数字制造的微流控平台，用于完整癌症切片培养物的多重药物测试，并展示了该平台在评估人胶质瘤异种移植和患者肿瘤活检切片培养物中药物反应的应用。这种方法保留了大部分组织微环境，并且能够在手术数天内快速提供结果，以指导有效初始治疗方案的选择。我们的结果建立了一个有用的癌症药物测试和开发临床前平台，具有改善癌症个性化医疗的潜力。
